Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

Recent & Breaking News (TSXV:BTI.H)

biOasis Secures DTC Eligibility

Marketwired May 8, 2014

biOasis Delivers siRNA to the Brain Using its Transcend Peptide Vector

Marketwired May 6, 2014

biOasis Delivers siRNA to the Brain Using its Transcend Peptide Vector

Marketwired May 6, 2014

biOasis Discovers the Keys to Transcend to Advance Its Program for the Delivery of Therapeutics Across the Blood-Brain Barrier

Marketwired April 24, 2014

biOasis Discovers the Keys to Transcend to Advance Its Program for the Delivery of Therapeutics Across the Blood-Brain Barrier

Marketwired April 24, 2014

BTV-Business Television - biOasis Technologies Enters into License Agreement with a Major Pharmaceutical Company

Newsfile April 4, 2014

biOasis Presents Results From It's BT2111 Program at International Cancer Research Conference

Marketwired April 3, 2014

biOasis Presents Results From It's BT2111 Program at International Cancer Research Conference

Marketwired April 3, 2014

biOasis Technologies (V.BTI) gains 5% on obtaining LSD-therapeutic patent

Gaalen Engen March 27, 2014

biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada

Marketwired March 27, 2014

biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada

Marketwired March 27, 2014

biOasis Enters Into a License Agreement With Medimmune for Second Generation Versions of biOasis's Transcend

Marketwired March 17, 2014

biOasis to Begin Trading on OTCQX® Marketplace in the U.S.

Marketwired February 24, 2014

biOasis Technologies Begins Trading on OTCQX®

PR Newswire February 24, 2014

Liolios Group Appoints Wojtek Nowak as Managing Director of Canada

Marketwired December 17, 2013

Option Grant-biOasis Technologies Inc.

Marketwired December 4, 2013

Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone

Marketwired November 12, 2013

BTV-Business Television - biOasis Technologies Breaking Through Brain Cancer

Newsfile November 8, 2013

biOasis Presents Research Results on BT2111 (Transcend-Trastuzumab) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Marketwired October 17, 2013

biOasis Engages Liolios Group to Lead New Investor Relations Program

Marketwired October 1, 2013